Aspect Biosystems
Bioprinting Tissue Therapeutics
Vancouver, Canada · Founded 2013 · $202.8M raised
- Headquarters
- Vancouver
- Employees
- 51–200
- Founded
- 2013
- Business Model
- B2B
- Website
- aspectbiosystems.com
- Total Funding
- $202.8M
- Last Round
- $115.0M Series BJan 2025
- Rounds
- 3
About
Aspect Biosystems is a Canadian biotechnology company founded in 2013 at the University of British Columbia, pioneering the development of bioprinted tissue therapeutics. The company uses proprietary microfluidic bioprinting technology to create implantable tissues designed to replace, repair, or supplement biological function. Their lead programs target metabolic and endocrine diseases, and they have partnered with Novo Nordisk and raised over US$350M in capital.
Summary
Aspect Biosystems is a Biotech company based in Vancouver, Canada, founded in 2013. It has raised $202.8M in total across 3 rounds, most recently a $115.0M Series B round in Jan 2025. Investors include Dimension Capital, Government of Canada and Government of British Columbia.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...